When the number on the scale is moving, bone health is easy to overlook. Bone changes are usually silent, and a smaller appetite leaves fewer chances to get calcium, vitamin D, protein, and other nutrients.
So, do GLP-1 medications weaken bones? The findings depend on who was studied, which medication and dose they received, how much weight they lost, whether they exercised, and whether researchers measured bone density or actual fractures.
That uncertainty is a reason to get the basics right. It is not a reason to panic or assume that everyone taking a GLP-1 medication needs the same supplement plan.
There is no single GLP-1 bone verdict
A 2025 joint advisory from four professional organizations identifies nutrition, resistance exercise, and preservation of muscle and bone as priorities during GLP-1 treatment. It also emphasizes individualized assessment and follow-up. [1]
Four findings show why the details matter:
1. Fracture results are reassuring, but the evidence is narrow. A 2025 meta-analysis combined 44 randomized trials involving 47,823 adults with type 2 diabetes. Across 292 fractures, GLP-1 receptor agonists were associated with a lower pooled fracture risk than placebo or other diabetes medicines (risk ratio 0.77; 95% CI 0.61–0.96). Fractures were uncommon, and the trials varied in medication, dose, comparator, and duration. The result does not establish protection for people without diabetes using current obesity-dose regimens. [2]
2. Newer real-world studies point in different directions. In 46,177 adults age 65 or older with type 2 diabetes, starting a GLP-1 receptor agonist was associated with an 11% higher fragility-fracture risk than starting an SGLT2 or DPP-4 inhibitor over a median 34.7 months (hazard ratio 1.11; 95% CI 1.01–1.21). In a separate matched study of 344,762 adults with type 2 diabetes, GLP-1 receptor agonist use was associated with a 9% lower femur-fracture risk than DPP-4 inhibitor use over a mean 40 months (hazard ratio 0.91; 95% CI 0.85–0.98). A third study found lower major osteoporotic-fracture rates with semaglutide versus selected comparators in people with obesity and type 2 diabetes, but no significant association in those without diabetes. These were observational analyses, so unmeasured differences between groups may remain after statistical adjustment. [3] [4] [5]
3. Bone density may still change in higher-risk adults. In a 52-week trial, 64 adults already at increased fracture risk received semaglutide 1 mg weekly or placebo. The groups did not differ significantly in the primary bone-formation marker. Hip bone mineral density was lower with semaglutide (estimated treatment difference −0.020 g/cm²; 95% CI −0.032 to −0.008), and spine density was also lower. The semaglutide group lost 6.8 kg more than the placebo group. This was a small, selected group—mostly postmenopausal women—and the trial measured bone density, not fractures. [6]
4. One of the most practical findings involved exercise. Another trial enrolled 195 adults with obesity but without diabetes. After an eight-week low-calorie diet, participants received liraglutide 3 mg daily, a structured exercise program, both, or placebo for 52 weeks. The combination group had the greatest estimated total weight loss, 16.9 kg over the full 60 weeks, without a statistically significant additional reduction in hip or spine bone density versus placebo. Bone density still declined at some sites, and this was a secondary analysis with no fracture outcome. It supports making exercise part of the plan; it does not prove that exercise prevents every bone change. [7]
The useful conclusion: current research does not support a blanket claim that GLP-1 medicines either damage or protect everyone’s bones. Fracture risk and bone-density change are different outcomes. None of these studies tested WrenLife Multi+, and none shows that a dietary supplement prevents medication-associated bone loss.
Know the daily calcium target
U.S. recommended calcium intake varies by age and sex. These totals are for generally healthy adults and include food and supplements together. A clinician may recommend a different plan for a specific medical need. [8]
| Adults | Calcium per day |
|---|---|
| Ages 19–50 | 1,000 mg |
| Men ages 51–70 | 1,000 mg |
| Women ages 51–70 | 1,200 mg |
| Adults age 71 and older | 1,200 mg |
The recommended vitamin D intake is 600 IU (15 mcg) daily for adults ages 19–70 and 800 IU (20 mcg) at age 71 and older. These are total-intake recommendations, not instructions to take that amount as a supplement. Treatment of a diagnosed deficiency may require a different plan. [9]
Make a smaller plate work harder
When meal size shrinks, each choice has more work to do. Yogurt, milk or calcium-fortified soy milk, calcium-set tofu, and canned fish with edible bones can add meaningful calcium without requiring a large meal. Amounts vary by product, so check the label. Examples from the NIH food table include: [8]
| Food and portion | Approximate calcium |
|---|---|
| Plain low-fat yogurt, 8 ounces | 415 mg |
| Calcium-fortified soy milk, 1 cup | 299 mg |
| Firm tofu made with calcium sulfate, ½ cup | 253 mg |
A useful first move is simple: choose one calcium-containing food for a meal you already tolerate. A registered dietitian can help fit calcium, protein, and overall nutrition into a reduced appetite.
Give your bones a reason to work
Weight-bearing movement and muscle-strengthening exercise do different jobs. Brisk walking and stair climbing are weight-bearing; resistance bands, weights, and appropriately chosen body-weight exercises build strength. The 2025 professional advisory proposes a goal of strength training at least three times weekly plus at least 150 minutes of moderate aerobic activity each week, adjusted to the person’s fitness and physical capacity. [1]
Start at a level you can repeat. Get individualized guidance if you have osteoporosis, a previous fracture, balance problems, or significant pain. Some high-impact activities and spinal movements may be unsuitable. [10]
Count Multi+ honestly
The 2025 joint advisory says vitamin D, calcium, vitamin B12, or a multivitamin-mineral supplement may be considered when those nutrients are at risk, with the choice and dose tailored to the individual. That is expert guidance, not a trial of any supplement, and the advisory did not test or endorse Multi+. [1]
WrenLife GLP-1 Support Multi+ is a daily multivitamin with 19 vitamins and minerals listed on its Supplement Facts panel. Each two-tablet serving provides: [11]
- Vitamin D3: 20 mcg (800 IU), or 100% Daily Value—an excellent source of vitamin D.
- Calcium: 220 mg, or 17% Daily Value—a good source of calcium.
- Phosphorus: 110 mg, or 9% Daily Value.
The “excellent source” and “good source” terms follow the federal nutrient-content definitions. [12]
Think of Multi+ as one line in the daily total. As an illustration, not a prescription: 220 mg from Multi+, 415 mg from 8 ounces of plain low-fat yogurt, and 299 mg from a cup of calcium-fortified soy milk add up to approximately 934 mg before other foods. Food values vary, so check labels; the right target and supplement plan depend on the individual.
The finished formula has not been evaluated in a clinical trial. Its nutrient amounts do not establish that it prevents bone-density changes, fractures, or medication side effects. It also does not replace food, protein, or exercise.
Know what your routine covers: View the complete Supplement Facts and decide with your clinician how Multi+ fits your daily total.
Try this five-minute bone-health check
- Find your calcium target in the table above.
- Choose one calcium-containing food for tomorrow.
- Put one weight-bearing or resistance session on your calendar.
- Bring every supplement label to your next visit before adding more.
Discuss persistent difficulty eating, a previous low-trauma fracture, known low bone density, or concerns about rapid weight loss with your healthcare team. Medication decisions belong with your prescriber.
Using Multi+: Follow the label: two tablets daily with a meal, or as directed by your healthcare provider. Avoid combining it with another multivitamin, prenatal, or high-dose B-complex unless your clinician advises it. Multi+ contains 3,000 mcg biotin, which can interfere with certain laboratory tests; tell your clinician and laboratory before bloodwork. Review supplement use with your clinician if you take medications, have a medical condition, are pregnant, or are nursing. [11] [13]
Educational information only. WrenLife sells the product discussed here. Individual nutrition, exercise, and bone-health needs vary.
References
- Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory. Obesity. 2025;33:1475–1503. Read the advisory.
- Zhang Y, et al. GLP-1 receptor agonist use and fracture risk in type 2 diabetes: meta-analysis of randomized trials. Bone. 2025;192:117338. Read the abstract.
- Meron MK, et al. GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2026;111(7):1949–1958. Read the study.
- Chang YJ, et al. Association between GLP-1 receptor agonists and femur fracture risk in type 2 diabetes: a large-scale target trial emulation. Bone. 2026;207:117851. Read the study.
- Huang YN, et al. Associations of semaglutide with skeletal outcomes in people with obesity, with and without type 2 diabetes: a target trial emulation. Diabetes Obes Metab. 2026;28(7):5834–5847. Read the study.
- Hansen MS, et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk. EClinicalMedicine. 2024;72:102624. Read the trial.
- Jensen SBK, et al. Bone health after exercise, liraglutide, or their combination: a randomized trial secondary analysis. JAMA Network Open. 2024;7:e2416775. Read the study.
- NIH Office of Dietary Supplements. Calcium: Health Professional Fact Sheet.
- NIH Office of Dietary Supplements. Vitamin D: Health Professional Fact Sheet.
- Bone Health & Osteoporosis Foundation. Exercise for strong bones.
- WrenLife. GLP-1 Support Multi+ product page and Supplement Facts panel.
- Electronic Code of Federal Regulations. 21 CFR 101.54: Nutrient-content claims.
- NIH Office of Dietary Supplements. Biotin: Health Professional Fact Sheet.
Evidence, regulatory sources, and current product label checked September 22, 2026.
